Myelopid & MP-1–MP-6Миелопид / миелопептиды
A family of peptides from bone marrow. Myelopid is the original mixture, and MP-1 through MP-6 are individual peptides.
What the studies found
Animal research · 2026
Spinorphin reduced migraine-like responses in rats
- Migraine-like responses
- Mechanical hypersensitivity and CGRP-related measures reducedRat model
- Opioid-receptor involvement
- Effects attenuated by nalmefene
- Sumatriptan combination
- Greater inhibition of capsaicin-evoked CGRP releaseEx vivo endpoint; not human combination efficacy
Spinorphin reduced mechanical hypersensitivity, c-Fos, CGRP and meningeal mast-cell degranulation in a rat migraine model. Nalmefene attenuated these effects. In ex vivo preparations, Spinorphin reduced capsaicin-evoked CGRP release and enhanced sumatriptan’s inhibitory effect on that endpoint.
Study notes · methods, sources and limitations
Participants or model Male Wistar rats with nitroglycerin-induced migraine-like responses; complementary ex vivo hemiskull preparations.
Important limitations
- Experimental rat and ex vivo findings, not a human migraine trial. A combined effect on CGRP release is not established clinical synergy with sumatriptan. These are Spinorphin results, not results for every myelopeptide.
The European journal of neuroscience 64(8) · Journal publication
Animal research · 2026
Spinorphin reduced experimental seizures and associated neurochemical changes
- Models
- Two acute seizure models: pentylenetetrazole and penicillin
- Seizure activity
- Behavioral seizures and cortical spike frequency reducedNumerical reduction not supplied by the abstract
- Memory
- Passive-avoidance retention improved
Spinorphin reduced behavioral seizures and cortical epileptiform spike frequency, improved passive-avoidance retention, and altered glutamate, GABA and inflammatory/oxidative markers. Nalmefene substantially attenuated the effects but did not fully reverse them, suggesting both opioid-related and other mechanisms.
More reported outcomes
- Nalmefene challenge
- Substantial but incomplete attenuation of effects
Study notes · methods, sources and limitations
Participants or model Rat pentylenetetrazole- and penicillin-induced acute seizure models.
Important limitations
- Acute rat seizure models, not clinical epilepsy evidence. The abstract does not provide numerical effect sizes or group-specific seizure counts. Spinorphin results cannot be assigned to all members of the myelopeptide family.
Neurochemical research 51(6) · Journal publication
Lab research · 2000
A new endogenous differentiating factor (myelopeptide-4) for myeloid cells.
MP-4 (FRPRIMTP), isolated from porcine marrow culture, altered differentiation markers and morphology in HL-60 and K-562 leukemia cell lines. This was not a leukemia treatment trial.
Study notes · methods, sources and limitations
Participants or model Human leukemia cell lines; porcine marrow-derived peptide
Important limitations
- Preclinical findings do not establish human benefit or safety. Abstract only. Full methods and independent replication remain unconfirmed.
FEBS letters · Indexed abstract
About Myelopid & MP-1–MP-6
Names in this research collection
Myelopid · MP-1 · MP-2 · MP-3 · MP-4 · MP-5 · MP-6 · Bivalen · Seramil · LVV-H3 · LVV-hemorphin-3 · Spinorphin · Tynorphin
Research background
A marrow-peptide family separating the original mixture from defined isolates and later synthetic research. Each member needs its own evidence.
- Compound class
- Peptide research family
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
No human treatment trial assessed for this family
Study methods
Member-specific studies; patents and archival leads identified separately
Independent replication
Independent replication not established by the records collected here
Source access
Primary abstracts, selected full texts, patents and explicit retrieval targets
Safety evidence
Cell and animal effects do not establish human safety; analogues may differ
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Animal research · 2026
Spinorphin Ameliorates Nitroglycerin-Induced Migraine-Like Responses and Trigeminovascular Neuroinflammation Potentially Through Opioid Receptor-Mediated Mechanisms
Spinorphin reduced mechanical hypersensitivity, c-Fos, CGRP and meningeal mast-cell degranulation in a rat migraine model. Nalmefene attenuated these effects. In ex vivo preparations, Spinorphin reduced capsaicin-evoked CGRP release and enhanced sumatriptan’s inhibitory effect on that endpoint.
Study notes and original source
Spinorphin Ameliorates Nitroglycerin-Induced Migraine-Like Responses and Trigeminovascular Neuroinflammation Potentially Through Opioid Receptor-Mediated Mechanisms
· Journal publication
Demir C, Torun IE, Baranoglu Kilinc Y, Kilinc E · The European journal of neuroscience 64(8)
Spinorphin reduced mechanical hypersensitivity, c-Fos, CGRP and meningeal mast-cell degranulation in a rat migraine model. Nalmefene attenuated these effects. In ex vivo preparations, Spinorphin reduced capsaicin-evoked CGRP release and enhanced sumatriptan’s inhibitory effect on that endpoint.
Results and tables
Reported findings and study design
Spinorphin reduced mechanical hypersensitivity, c-Fos, CGRP and meningeal mast-cell degranulation in a rat migraine model. Nalmefene attenuated these effects. In ex vivo preparations, Spinorphin reduced capsaicin-evoked CGRP release and enhanced sumatriptan’s inhibitory effect on that endpoint.
Population or model Male Wistar rats with nitroglycerin-induced migraine-like responses; complementary ex vivo hemiskull preparations.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Migraine-like responses | Mechanical hypersensitivity and CGRP-related measures reduced | Rat model |
| Opioid-receptor involvement | Effects attenuated by nalmefene | |
| Sumatriptan combination | Greater inhibition of capsaicin-evoked CGRP release | Ex vivo endpoint; not human combination efficacy |
Experimental rat and ex vivo findings, not a human migraine trial. A combined effect on CGRP release is not established clinical synergy with sumatriptan. These are Spinorphin results, not results for every myelopeptide.
Source for these results ↗ · Reviewed 2026-10-31
- Population / setting
- Male Wistar rats with nitroglycerin-induced migraine-like responses; complementary ex vivo hemiskull preparations.
- Source reviewed
- Primary publication metadata and indexed abstract checked through Europe PMC on 31 October 2026. No unavailable effect sizes inferred.
Study limitations
- Experimental rat and ex vivo findings, not a human migraine trial. A combined effect on CGRP release is not established clinical synergy with sumatriptan. These are Spinorphin results, not results for every myelopeptide.
Reviewed 2026-10-31.
Animal research · 2026
Spinorphin Attenuates Acute Experimental Seizures and Associated Neurochemical Alterations: Possible Involvement of Opioid Receptors
Spinorphin reduced behavioral seizures and cortical epileptiform spike frequency, improved passive-avoidance retention, and altered glutamate, GABA and inflammatory/oxidative markers. Nalmefene substantially attenuated the effects but did not fully reverse them, suggesting both opioid-related and other mechanisms.
Study notes and original source
Spinorphin Attenuates Acute Experimental Seizures and Associated Neurochemical Alterations: Possible Involvement of Opioid Receptors
· Journal publication
Torun IE, Baranoglu Kilinc Y, Kilinc E, Ankarali S · Neurochemical research 51(6)
Spinorphin reduced behavioral seizures and cortical epileptiform spike frequency, improved passive-avoidance retention, and altered glutamate, GABA and inflammatory/oxidative markers. Nalmefene substantially attenuated the effects but did not fully reverse them, suggesting both opioid-related and other mechanisms.
Results and tables
Reported findings and study design
Spinorphin reduced behavioral seizures and cortical epileptiform spike frequency, improved passive-avoidance retention, and altered glutamate, GABA and inflammatory/oxidative markers. Nalmefene substantially attenuated the effects but did not fully reverse them, suggesting both opioid-related and other mechanisms.
Population or model Rat pentylenetetrazole- and penicillin-induced acute seizure models.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Models | Two acute seizure models: pentylenetetrazole and penicillin | |
| Seizure activity | Behavioral seizures and cortical spike frequency reduced | Numerical reduction not supplied by the abstract |
| Memory | Passive-avoidance retention improved | |
| Nalmefene challenge | Substantial but incomplete attenuation of effects |
Acute rat seizure models, not clinical epilepsy evidence. The abstract does not provide numerical effect sizes or group-specific seizure counts. Spinorphin results cannot be assigned to all members of the myelopeptide family.
Source for these results ↗ · Reviewed 2026-10-31
- Population / setting
- Rat pentylenetetrazole- and penicillin-induced acute seizure models.
- Source reviewed
- Primary publication metadata and indexed abstract checked through Europe PMC on 31 October 2026. No unavailable effect sizes inferred.
Study limitations
- Acute rat seizure models, not clinical epilepsy evidence. The abstract does not provide numerical effect sizes or group-specific seizure counts. Spinorphin results cannot be assigned to all members of the myelopeptide family.
Reviewed 2026-10-31.
Lab research · 2000
A new endogenous differentiating factor (myelopeptide-4) for myeloid cells.
MP-4 (FRPRIMTP), isolated from porcine marrow culture, altered differentiation markers and morphology in HL-60 and K-562 leukemia cell lines. This was not a leukemia treatment trial.
Study notes and original source
A new endogenous differentiating factor (myelopeptide-4) for myeloid cells.
Strelkov LA, Mikhailova AA, Fonina LA, Petrov RV · FEBS letters
MP-4 (FRPRIMTP), isolated from porcine marrow culture, altered differentiation markers and morphology in HL-60 and K-562 leukemia cell lines. This was not a leukemia treatment trial.
- Population / setting
- Human leukemia cell lines; porcine marrow-derived peptide
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Lab research · 2005
Induction of differentiation in leukemic cell strains with myelopeptide-4.
MP-4 increased differentiation-associated antigens and mature-cell features in leukemia cell cultures, with phagocytosis also examined. The report extends laboratory characterization rather than demonstrating clinical efficacy.
Study notes and original source
Induction of differentiation in leukemic cell strains with myelopeptide-4.
Kirilina EA, Suvorov NI, Popova SS, Khaidukov SV, Rapoport EM, Fonina LA, Mikhailova AA · Bulletin of experimental biology and medicine
MP-4 increased differentiation-associated antigens and mature-cell features in leukemia cell cultures, with phagocytosis also examined. The report extends laboratory characterization rather than demonstrating clinical efficacy.
- Population / setting
- HL-60, K-562 and THP-1 cell lines
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Lab research · 2006
Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus.
MP-2 (LVVYPW) restored IL-2 production and receptor expression in experimentally suppressed human T cells. Human-derived cells do not make this a human treatment trial.
Study notes and original source
Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus.
Mikhailova AA, Belevskaya RG, Kalyuzhnaya M, Fonina LA, Liashenko VA, Petrov RV · Journal of immunotherapy (Hagerstown, Md. : 1997)
MP-2 (LVVYPW) restored IL-2 production and receptor expression in experimentally suppressed human T cells. Human-derived cells do not make this a human treatment trial.
- Population / setting
- Human T-cell cultures exposed to tumor-conditioned medium or measles virus
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Animal research · 2002
Effect of myelopeptide-2 on the development of spontaneous and urethane-induced tumors in mice.
MP-2 altered the appearance and number of spontaneous and urethane-induced lung tumors in mice. Laboratory tumor outcomes do not establish cancer prevention or treatment in people.
Study notes and original source
Effect of myelopeptide-2 on the development of spontaneous and urethane-induced tumors in mice.
Mikhailova AA, Kirilina EA, Morozova OV, Turusov VS · Bulletin of experimental biology and medicine
MP-2 altered the appearance and number of spontaneous and urethane-induced lung tumors in mice. Laboratory tumor outcomes do not establish cancer prevention or treatment in people.
- Population / setting
- Mice; spontaneous and carcinogen-induced tumors
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Animal research · 1990
Participation by opioids in the immunostimulatory activity of myelopeptides.
Antibody-stimulating material and beta-endorphin eluted in different chromatographic fractions. The original mixture’s opioid-related effects cannot be assigned to every defined MP-1–MP-6 peptide.
Study notes and original source
Participation by opioids in the immunostimulatory activity of myelopeptides.
Zakharova LA, Belevskaya RG, Yanovskii OG · Biomedical science
Antibody-stimulating material and beta-endorphin eluted in different chromatographic fractions. The original mixture’s opioid-related effects cannot be assigned to every defined MP-1–MP-6 peptide.
- Population / setting
- Mice, marrow peptide fractions and chromatography
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Experiment described in a patent · 2002
Myelopeptides and their therapeutic use — US6469137B1
MP-3, MP-4, MP-5 and MP-6 were described as marrow-culture isolates with nonuniform immune, differentiation and antiviral assay results. The patent does not establish that the mixture or every member shares these activities.
MP-4 leukemia-cell differentiation · Approximately 60% mature monocyte/macrophage forms reported among the examined cells · In-vitro morphology endpoint, not a leukemia remission rate
Study notes and original source
Myelopeptides and their therapeutic use — US6469137B1
· Primary source linked above
MP-3, MP-4, MP-5 and MP-6 were described as marrow-culture isolates with nonuniform immune, differentiation and antiviral assay results. The patent does not establish that the mixture or every member shares these activities.
Results and tables
Reported patent results
Reported findings
MP-4 induced a differentiation-like phenotype in leukemia cells; the individual myelopeptides did not act uniformly across the assays.
Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.
Population or model Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MP-4 leukemia-cell differentiation | Approximately 60% mature monocyte/macrophage forms reported among the examined cells | In-vitro morphology endpoint, not a leukemia remission rate |
| Short-term viability | No visible damage reported for the tested MP-3–MP-6 cell-culture conditions | A limited cell assay, not clinical or long-term safety · 24-hour observation |
Cell differentiation, assay response and lack of visible short-term damage do not establish efficacy or safety of Myelopid in patients. Individual peptides and mixtures must remain distinct.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.
- Source reviewed
- Selected original-source text checked; full methodological review pending.
Study limitations
- Patent efficacy proposals are not clinical evidence.
- Commercial product names require formulation-specific confirmation.
Reviewed 2026-11-06.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗